Chrome Plugin Live! Redefine the way you read FinTwit 🚀 Install Now
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.
NASDAQ
Unprofitable
Unprofitable
3B
Biotechnology
Next Earning date - 07 Nov 2024
3B
Biotechnology
Next Earning date - 07 Nov 2024
Relative Strenght
25Volume Buzz
-40%Earning Acce
NoDist 52w H.
19%